Robust Fourth-Quarter Performance Driven by Strength in Acthar ® Gel 1  and XIAFLEX ® 2
DUBLIN , March 27, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ ® (terlipressin)...
Manuscript appears in a peer-reviewed journal for the first time
DUBLIN , Feb. 24, 2026 /PRNewswire/ -- Keenova Therapeutics plc is presenting clinical data on plantar fibromatosis at the American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting, taking...
DUBLIN , Feb. 16, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript presenting real-world evidence on treatment patterns for patients with plantar fibromatosis....
DUBLIN , Jan. 21, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that it reached a milestone: 100,000 patients with Peyronie's disease (PD) have been prescribed XIAFLEX ®...
Analysis to Be Presented at the American Association for Hand Surgery Meeting
DUBLIN , Nov. 12, 2025 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today announced that management will present at the Jefferies Global Healthcare Conference in London...
Delivers Third Quarter Net Sales of $753.1 Million, Driven by Acthar ® Gel (repository corticotropin injection) Growth and the Inclusion of Two Months of Endo Product Net Sales
Keenova Focused on Advancing Therapies to Address Unmet Patient NeedsÂ